Clinical Trial Update: Assess Bioequivalence of Two Formulations of Doxorubicin Hydrochloride Liposome in Female Patients With Ovarian Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial completed evaluating bioequivalence between two formulations of liposomal doxorubicin in female patients with ovarian cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• DOXORUBICIN HYDROCHLORIDE LIPOSOME (DOXORUBICIN HYDROCHLORIDE)

Snippet

Sponsor: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Conditions: Ovarian Cancer | Phase 1 | Status: COMPLETED